Navigation Links
Gene tests and brain imaging reveal early dementia

Dementia diseases develop insidiously and are generally discovered when the memory has already started to deteriorate. New research form Karolinska Institutet shows, however, that approaching Alzheimer's can be detected several years before the symptoms manifest themselves.

Dementia involves a serious deterioration of mental function caused by some kind of dementia disease of the brain, of which Alzheimer's is the most common. Although there is currently no cure for Alzheimer's, it is possible to inhibit its development if the treatment is given early enough. However, with today's diagnostics, it is very difficult to identify people with early Alzheimer's.

A new doctoral thesis by Johanna Lind, Karolinska Institutet in Sweden, now shows that genetic mapping and brain imagery can be used to identify people who will develop dementia even before any clinical symptoms appear.

"This is a crucial step towards the better diagnosis of Alzheimer's," she says. "If the method is developed it can help us find the people who'd benefit most from treatment in good time."

The method is based on the well-established fact that the APOE protein affects the risk of developing Alzheimer's. APOE is a lipid-transporting protein important in, amongst other things, the repair of cerebral neurons. Roughly one person in five carries a genetically determined variant of APOE that is associated with an increased risk of Alzheimer's.

In her study, Johanna Lind was able to show that some of the people in this risk group had reduced parietal lobe activity, detectable using an MR camera, and that these same people were the ones who went on to suffer memory deterioration two to three years later.

"It's surprisingly difficult to diagnose Alzheimer's with any certainty, but things are made easier if you know who runs the greatest risk," she says. "If genetic mapping, MRI and cognitive tests all suggest approaching Alzheimer's, it might be an
'"/>

Source:Karolinska Institutet


Page: 1 2

Related biology news :

1. Transgenic plants remove more selenium from polluted soil than wild plants, new tests show
2. UN successfully tests green pesticide against locusts
3. Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned
4. Free HIV tests cheaper than charging when goal is preventing AIDS
5. Embryo tests give parents the choice
6. Chemical tests of cell growth enter third dimension
7. Light-based probe sees early cancers in first tests on human tissue
8. Soft-cell approach cuts animal tests
9. Controversial drug shown to act on brain protein to cut alcohol use
10. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
11. Mouse brain tumors mimic those in human genetic disorder

Post Your Comments:
(Date:12/1/2009)... Antennas aren,t just for listening to the radio a...s to GPS devices. Research from North Carolina Sta...nna design creating shape-shifting antennas that ...ing from public safety to military deployment. , ...als, but there are limitations to how far they can...
(Date:11/30/2009)...hose extra helpings of gravy and dessert at the ho...ine than previously thought. According to a new re...SEB Journal ( http://www.fasebj.org ), a diet tha... genes that ultimately cause our bodies to store t... double-whammy as the already difficult task of co...
(Date:11/30/2009)...This release is available in German . , The...aborative Research Centres as of 1 January 2010. T...nts Committee in Bonn. The new centres will initia...illion. In addition, 20 percent overhead funding f...roject. The centres, research topics range from mo...
Breaking Biology News(10 mins):Shape shifters: Researchers create new breed of antennas 2Happy holidays from the groaning board; Western diets turn on fat genes 2DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9Physiological response may explain why some severely obese patients overeat 48353 1Physiological response may explain why some severely obese patients overeat 48353 2Hypertension among lower status employees lingers well into retirement 8771 1Hypertension among lower status employees lingers well into retirement 8771 2Hypertension among lower status employees lingers well into retirement 8771 3Alzheimers and Even Mild Dementia Hasten Death 48350 1Alzheimers and Even Mild Dementia Hasten Death 48350 2
...L HILL Researchers at the University of North Car...ified a compound that could be modified to treat o...red how a particular gene mutation contributes to ...ent apply to a type of brain tumor called secondar...a larger group of brain tumors called malignant gl...
...d Hughes Medical Institute researchers have design...causes Huntington,s disease without damaging that ...alth and vitality of neurons. Laboratory studies s...educe production of the damaging Huntingtin protei...er 25 percent of patients might benefit from one o...
...icial heart pacemakers have saved and extended the... shortcomings such as a fixed pulse rate and a l... be possible? , Richard Robinson and colleagues ...s certainly think so, and their work published in ...ings the dream a step closer to reality. , The bo...
Other Biology News:UNC study: Scientists identify chemical compound that may stop deadly brain tumors 2New therapeutic strategy could target toxic protein in most patients with Huntington's disease 2New therapeutic strategy could target toxic protein in most patients with Huntington's disease 3New therapeutic strategy could target toxic protein in most patients with Huntington's disease 4Towards a natural pacemaker 2
(Date:12/2/2009)...ire/ -- S*BIO Pte Ltd today announced data present...t The American Society of Hematology 51st Annual M...ill be presented on the clinical results from the ...its safety, tolerability and pharmacokinetic/pharm...from 100 to 600 mg. These doses were administered ...
(Date:12/2/2009)...FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ...tical company focused on endocrine therapy and onc... Administration (FDA) has granted Fast Track desig...r compound, perifosine (KRX-0401), for the treatme...Biopharmaceuticals, Inc. ("Keryx") ( KERX), is AEt...
(Date:12/2/2009)...re/ -- According to the National Institute of Heal...d with diabetes already have some stage of diabeti...e retina caused by leaky blood vessels, is a major... one of the most feared diabetic complications. I...d diabetes for 10 years or more will experience so...
(Date:12/1/2009)...re/ -- Reportlinker.com announces that a new marke..., Chromium - Global Market Trends ,, ht...al-Market-Trends.html ,, Worldwide demand for ...l, while growth in aerospace and industrial gas tu...mium metal. Environmental constraints and rapid de...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9
... Efficacy Will Drive Prescription Rates, According...urces, WALTHAM, Mass., Feb. 13 Decision Resource...y firms focusing on pharmaceutical and,healthcare ...y 2009,Centocor/Janssen-Cilag,s ustekinumab will b...2011. Ustekinumab will achieve gold standard statu...
...e Nanotech, Inc.,(OTC Bulletin Board: AVNA), a lea... announced today that at a special meeting of shar... on February 12, 2008, a proposal was,approved to ...l stock from,100,000,000 shares to 225,000,000 sha...the meeting were voted in favor of the proposal to...
... American Country to Approve Treatment, BASINGSTO... 13, Shire plc (LSE: SHP)(NASDAQ: SHPGY )(TSX: SH... announced that ELAPRASE(R),(idursulfase), a human...unter syndrome, has been approved for commercial s...ection against Sanitary Risk (COFEPRIS).,Mexico is...
Other Biology Technology:Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011 2Advance Nanotech Announces Shareholder Proxy Vote Results 2Advance Nanotech Announces Shareholder Proxy Vote Results 3Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 2Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 3Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 4
Sheep Growth Hormone from Cell Sciences
Rat Anti-Mouse Semaphorin 6B Monoclonal Antibody, Unconjugated, Clone 256537 from R&D Systems
Mouse Anti-Human ADAM10 Ectodomain Monoclonal Antibody, Unconjugated, Clone 163003 from R&D Systems
Goat Anti-Human PLUNC Polyclonal Antibody, Biotin Conjugated from R&D Systems
Biology Products: